AMVUTTRA
vutrisiransiRNATTR-targeting RNAi
ATTR Cardiomyopathy
Phase 3
1 program·1 trial·View drug →
DashboardSell4,128$117.65−$485.7KBuy3,509$153.68+$539.3KSell456,341$131.49−$60.0MSell56,884$147.46−$8.4MSell583,406$148.04−$86.4MSell21,832$113.52−$2.5MOption ex.1,815$106.25$192.8K NeuromuscularCo-Investigator$635.4K6NeuromuscularCo-Investigator$597.9K7NeuromuscularCo-Investigator$538.5K6NeuromuscularCo-Investigator$523.7K5NeuromuscularCo-Investigator$448.8K6NeurologyEquity / Ownership$431.2K6NeuromuscularCo-Investigator$311.9K4NeuromuscularCo-Investigator$309.3K4NeurologyCo-Investigator$301.1K6NeuromuscularEquity / Ownership$280.1K7
ALNYNASDAQ
Alnylam
Alnylam Pharmaceuticals, Inc. · Cambridge, MA · founded 2002
Alnylam Pharmaceuticals is a Cambridge, Massachusetts pioneer of RNA interference, a technology that "silences" a disease-causing gene by triggering the cell to destroy its messenger RNA before a harmful protein can be made. The company markets four approved siRNA drugs — ONPATTRO and AMVUTTRA for transthyretin amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria — with a pipeline that extends into cardiovascular, hypertension, and CNS diseases.
- Lead asset
- AMVUTTRA · Ph3 · ATTR Cardiomyopathy
- siRNA · TTR-targeting RNAi
- Pipeline
- 1 drug · 1 program
- 1 Cardio-Renal
- Modalities
- siRNA×1
FocusRare DiseaseCardio-Renal
$295.00+21.97%1Y
ALNY · daily close · illustrative · 2 catalysts marked
P3 readout+33%PDUFA+42%
1Y high$298.291Y low$240.52range$57.77(24%)past catalysts
Peers in this space
ARWR$2.2B
Arrowhead Pharmaceuticals
Rel.
0.46
Cardio-RenalsiRNA
1 programmatch: sector + modality
IONS$5.8B
Ionis
Rel.
0.62
Cardio-Renaloligonucleotide
1 programmatch: sector
ARDX$1.7B
Ardelyx
Rel.
0.61
Cardio-Renalsmall molecule
1 programmatch: sector
VERV$540M
Verve Therapeutics
Rel.
0.28
Cardio-Renalgene therapy
1 programmatch: sector
Pipeline & catalysts
Pipeline & catalysts
Pipeline by phase1programs
- Preclin0
- Ph10
- Ph20
- Ph31
- Filed0
- Approved0
Past catalyst impact
DateKindEventOutcome+1W+1M+6M
Feb 14, 2026ReadoutAMVUTTRA HELIOS-B Phase 3 Topline (ATTR-CM)Positive+33.4%+35.6%+27.7%
Apr 30, 2025PDUFAAMVUTTRA — PDUFA — ApprovedPositive+42.0%+27.4%+28.7%
Dec 31, 2024ReadoutAMVUTTRA — Phase 2b Topline Met Primary EndpointPositive+16.8%+24.9%+43.8%
Sep 2, 2024Enroll.AMVUTTRA — Pivotal Enrollment CompletePositive+5.6%+5.8%+3.0%
Oct 8, 2023Conf.AMVUTTRA — ASH Late-Breaker — Updated SurvivalNegative-9.7%-6.2%-3.7%
% change vs ticker close on the announcement date · backtest illustrative
Smart money
Insider activity
Insider activity · last 90 days
Form 4 trail · 7 transactions · 6 insiders
Net flow
−$157.2M
Buys
$539.3K
1 txns
Sells
$157.7M
5 txns
Largest
−$86.4M
10% Owner sell
Net flow per quarter · last 8Q
11 txns · sum −$117.41M
24Q325Q125Q326Q126Q2
buys · $42.12Msells · $159.53M
Insider · roleActionSharesPriceValueDate
N. Kowalski
COO
Apr 23, 2026
T. Tanaka
EVP
Apr 22, 2026
N. Kowalski
10% Owner
Apr 18, 2026
B. Mendoza
CEO
Mar 30, 2026
P. Chen
10% Owner
Mar 30, 2026
T. Müller
Director
Mar 13, 2026
C. Park
EVP
Mar 12, 2026
Congressional trading
Congressional trading · STOCK Act · last 365d
5 trades · 4 members
Est. net flow
−$2.63M
midpoint · brackets only
Buys
2
Sells
3
Party mix
3 D1 R1 I
Member · chamberActionBracket~ midpointOwnerDate · disclosure
I
Buy$1K–$15K~$8KspouseRep. R. Müller
House · VT
Apr 20, 2026
filed +19d
D
Sell$1.00M–$5.00M~$3.00MjointRep. P. Bowen
House · NJ
Apr 10, 2026
filed +32d
D
Sell$1K–$15K~$8KselfRep. P. Bowen
House · NJ
Mar 21, 2026
filed +29d
D
Sell$250K–$500K~$375KselfSen. E. Mendoza
Senate · AZ
Feb 5, 2026
filed +2d
R
Buy$500K–$1.00M~$750KselfSen. B. Tucker
Senate · TN
Dec 20, 2025
filed +20d
Source: Senate eFD & House Clerk PTR feeds · members must disclose within 45 days · midpoints reflect bracket midpoint, not actual transaction value
Top ETF holders
ETF holders · NAV disclosures
2 ETFs hold the position
Held by ETFs
$2.2M
aggregate position
Of market cap
0.01%
aggregate ETF share
Top holder
GNOM2.28%
Global X Genomics & Biotechnology
TickerETF · familyThemeNAV% of NAVPosition
GNOMGenomics$90.0M2.28%$2.1M
Global X Genomics & Biotechnology
VanEck
PBEBroad biotech$175.0M0.06%$105K
Invesco Dynamic Biotechnology
Invesco
Source: ETF NAV disclosures + quarterly 13F filings · narrow-theme ETFs disclose holdings daily; broad ETFs quarterly · % of NAV is the position weight inside the fund
KOL network
KOL network · CMS OpenPayments
22 physicians paid · 112 disclosed records
Total 2025+2024
$6.43M
YoY
+53%
Co-Investigator$3.48MEquity / Ownership$1.62MResearch Grant$776.1KSpeaking$255.7KConsulting$233.5KTravel & Lodging$66.5KFood & Beverage$5.7K
Physician · affiliationSpecialtyTop categoryTotalRecords
Dr. Henry Murphy
Yale Medical
Dr. Olivia Tanaka
Stanford Medicine
Dr. Priya Hoffman
Stanford Medicine
Dr. Liam Park
Memorial Sloan Kettering
Dr. Charles Goldstein
Mass General Hospital
Dr. Robert Singh
Johns Hopkins
Dr. Marcus Romano
Vanderbilt
Dr. Nadia Walsh
University of Washington
Dr. Rebecca Lindberg
Cleveland Clinic
Dr. Ahmed Romano
University of Washington
Source: CMS OpenPayments · quarterly drops · physicians identified by NPI · aggregated across all programs
Government & IP
Federal lobbying
Federal lobbying · LDA · last 8 quarters
$1.38M disclosed · 4 firms engaged
YoY change
+16%
last 4Q vs prior 4Q
24Q3Q425Q1Q2Q3Q426Q1Q2
Top lobbying firms · last 8Q
Forbes-Tate Partners$389K
5 quarters active
Thorn Run Partners$356K
5 quarters active
Cornerstone Government Affairs$320K
4 quarters active
Cassidy & Associates$318K
3 quarters active
Top issues lobbied
- Sunshine Act expansion$548K
- Prescription Drug User Fee programs$479K
- Inflation Reduction Act drug-price negotiation$356K
Source: Senate LDA database (lda.senate.gov) · quarterly registrant filings · spend is the company-wide total disclosed
Government contracts
Federal contracts · USAspending.gov
1 award · 1 agency
Total awarded
$27.6M
across all programs
Active
$27.6M
option periods incl.
Top agency
NIH / NIAID$27.6M
largest active: Vaccine Adjuvant Research — Phase 1 / 2
AgencyTitle · type · award IDStatusValueAwarded → ends
NIH / NIAIDactive$27.6MJul 2024→ May 2028
Vaccine Adjuvant Research — Phase 1 / 2
Grant · NIH-66098997
Source: USAspending.gov · SAM.gov · every federal contract / grant / cooperative agreement is public · values are obligated awards (may include option periods)
U.S. Patents
U.S. Patents · USPTO
9 granted · 6 pending
Total in portfolio
15
Granted in last 12mo
2
Expiring < 2yr
0
Nearest expiry
Apr 2033
Patent #Title · inventor · drugTypeStatus · filedExpiry
11,988,840Composition of Matter
Bispecific antibody compositions targeting AMVUTTRA
F. Voss + 1 · AMVUTTRA
grantedfiled Apr 2023
exp. Apr 2043
17.0y left
10,959,498Process
Continuous manufacturing process for AMVUTTRA
J. Park + 2 · AMVUTTRA
grantedfiled Apr 2024
exp. Apr 2044
18.0y left
US 2025/9815311 A1Composition of Matter
Therapeutic peptide compositions for AMVUTTRA
T. Goldstein · AMVUTTRA
pendingfiled Apr 2025
in prosecution
12,328,368Formulation
Stable lyophilized formulations of AMVUTTRA
T. Iyer + 3 · AMVUTTRA
grantedfiled Apr 2019
exp. Apr 2039
13.0y left
US 2023/4260558 A1Composition of Matter
Genome editing constructs encoding AMVUTTRA
C. Reyes + 1 · AMVUTTRA
pendingfiled Apr 2023
in prosecution
10,889,379Formulation
Stable lyophilized formulations of AMVUTTRA
D. Hoffman + 1 · AMVUTTRA
grantedfiled Apr 2018
exp. Apr 2038
12.0y left
11,338,418Composition of Matter
Small molecule modulators of AMVUTTRA
E. Romano · AMVUTTRA
grantedfiled Apr 2019
exp. Apr 2039
13.0y left
US 2021/2639912 A1Composition of Matter
Therapeutic peptide compositions for AMVUTTRA
J. Nguyen + 2 · AMVUTTRA
pendingfiled Apr 2021
in prosecution
showing 8 of 15 · full portfolio available on Pro
Source: USPTO PEDS & Patent Public Search · composition-of-matter is the headline asset · expiration = 20 years from filing
News
News
News · last 90 days
8 items from 5 categories
clinical2corporate2partnership2regulatory1lawsuit1
3d ago
ALNY receives Orphan Drug Designation for AMVUTTRA
FierceBiotech·regulatory
5d ago
ALNY reports topline results from Phase 2 trial of AMVUTTRA
Endpoints News$·clinical
6d ago
ALNY adds independent director to Board
Business Wire·corporate
21d ago
ALNY presents AMVUTTRA data at major medical conference
Endpoints News$·clinical
1mo ago
ALNY closes ex-U.S. rights deal worth $1.1 billion in milestones
PR Newswire·partnership
2mo ago
ALNY appoints new Chief Medical Officer
PR Newswire·corporate
2mo ago
ALNY announces strategic collaboration in rare disease
PR Newswire·partnership
2mo ago
Class-action complaint filed against ALNY alleging disclosure issues
STAT$·lawsuit
Sources: PR wires + biotech-trade publications + company IR · paywalled outlets ($) link to publisher · we never paraphrase the headline
Financials
Financials
Trading
Previous close
$295.00
Open
$295.00
Day Δ
+0.00
+0.00%
Day range
$292.94 – $297.06
52W range
$240.52 – $298.29
Avg daily volume
743K
Valuation & ownership
Enterprise value
$31.6B
Shares out
112.54M
Float
97.91M
Insider %
4.58%
Institutional %
64.58%
Beta
1.08
vs SPY · 52w
Balance sheet & burn
Cash + invest
$3.2B
Total debt
$1.9B
Debt / equity
7.58
Cash burn / Q
$120M
R&D spend TTM
$516M
16% of cash
ATM available
$7.6B
dilution risk
Earnings
EPS latest
$-0.13
EPS Δ vs prior
+0.18
EPS estimate
$-0.15
next quarter
EPS prior
$-0.31
Next earnings
May 11, 2026
Rev guidance
$432M